Evidence map›Paper›PMID 33386501›Full record

ArticleBiotechnology letters2021

Protein mass spectrometry reveals lycorine exerting anti-multiple-myeloma effect by acting on VDAC2 and causing mitochondrial abnormalities.

Hui Yi, Xiaokai Shen, Haiqin Wang, Saiqun Luo, Wancheng Guo, Peng Chen, Lei Hu, Long Liang, Yanfei Gong, Xiaojuan Xiao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. VDAC2: an emerging pivotal and multifaceted regulator in tumor biology.Apoptosis : an international journal on programmed cell death · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hui YiMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China.
Xiaokai ShenXiangya Medical School, Central South University, Changsha, China.
Haiqin WangMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China.
Saiqun LuoMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China.
Wancheng GuoXiangya Medical School, Central South University, Changsha, China.
Peng ChenXiangya Medical School, Central South University, Changsha, China.
Lei HuMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China.
Long LiangMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China. liang_long614@126.com.
Yanfei GongMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China. gongyanfei@csu.edu.cn.
Xiaojuan XiaoMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China. xiaojuan_xiao@csu.edu.cn.ORCID http://orcid.org/0000-0002-7058-297X
Jing LiuMolecular Biology Research Center & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China.
Central South University · CN

Funding

Fundamental Research Funds for Central Universities of the Central South University 2020zzts425National Natural Science Foundation of China 81600184National Natural Science Foundation of China 81970195
6 · The paper itself

Abstract

objectiveTwo-dimensional electrophoresis (2-DE) and MALDI-TOF/TOF mass spectrometry were performed to compare the proteomic alterations of lycorine-treated and control cells to further investigate the anti-multiple myeloma (MM) mechanisms of lycorine.

resultsMass spectrometry results showed that after lycorine treatment of MM cells, 42% of the differentially expressed proteins had subcellular localization, mainly, on mitochondria. Voltage-dependent anion-selective channel protein 2 (VDAC2), the most abundant protein in the outer mitochondrial membrane, was up-regulated after treatment with lycorine and was subsequently verified by western blot analysis. Further studies on mitochondria found that lycorine was able to increase abnormal mitochondria and increase mitochondrial membrane potential.

conclusionsLycorine can achieve the effect of resisting multiple myeloma by acting on VDAC2 and causing mitochondrial abnormalities.

Indexed as

Amaryllidaceae AlkaloidsAntineoplastic AgentsElectrophoresis, Gel, Two-DimensionalHumansMitochondriaMultiple MyelomaPhenanthridinesProteomeSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationVoltage-Dependent Anion Channel 2Amaryllidaceae AlkaloidsAntineoplastic AgentslycorinePhenanthridinesProteomeVDAC2 protein, humanVoltage-Dependent Anion Channel 22-DEAbnormal mitochondriaLycorineMALDI-TOF/TOF mass spectrometryMultiple myelomaVDAC2

Identifiers

PMID33386501
OpenAlexW3117195479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.